Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
---|---|
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00873834 |
This study is a comparative, double blind, placebo controlled trial of 6-months duration designed to evaluate 1) the effects of fluoxetine in 5 to 12 years old autistic children, 2) the effects of fluoxetine on serotoninergic parameters, 3) cerebral metabolic changes (rCBF measurements with PET) induced by the treatment.
Condition | Intervention | Phase |
---|---|---|
Autism |
Drug: fluoxetine Drug: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Fluoxetine : Clinical and Anatomy-Functional Therapeutic Effects in Children With Autism |
Estimated Enrollment: | 30 |
Study Start Date: | September 2009 |
Estimated Study Completion Date: | November 2011 |
Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Fluoxetine arm: Experimental
Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks. A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized |
Drug: fluoxetine
Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks. A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized |
placebo arm: Placebo Comparator
Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
|
Drug: placebo
Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
|
Ages Eligible for Study: | 5 Years to 12 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: CHABANE Nadia, MD | 01.40.03.22.92 | nadia.chabane@rdb.aphp.fr |
Contact: ZILBOVICIUS Monica, MD | 01 69 86 78 90 ext +33 | monica.zilbovicius@cea.fr |
France, Ile de France | |
Hopital Robert DEBRE | |
PARIS, Ile de France, France, 75019 |
Principal Investigator: | CHABANE Nadia, MD | Assistance Publique - Hôpitaux de Paris (Hopital Robert DEBRE) |
Responsible Party: | Department Clinical Research and Development ( Valérie MILLUL ) |
Study ID Numbers: | P030901, AOM 98082 |
Study First Received: | April 1, 2009 |
Last Updated: | May 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00873834 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
autism fluoxetine Comparative double blind placebo |
controlled trial anatomy-functional imaging children DSM-IV-R criteria for autism and CARS score (of 30 or above) |
Developmental Disabilities Neurotransmitter Agents Psychotropic Drugs Serotonin Uptake Inhibitors Serotonin Child Development Disorders, Pervasive Fluoxetine |
Autistic Disorder Mental Disorders Mental Disorders Diagnosed in Childhood Antidepressive Agents, Second-Generation Autism Antidepressive Agents |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors Pharmacologic Actions Child Development Disorders, Pervasive Fluoxetine |
Serotonin Agents Autistic Disorder Mental Disorders Therapeutic Uses Mental Disorders Diagnosed in Childhood Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |